Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 12, 1997, Pages 2714-2718

  Vandewoude, K ^a   Vogelaers, D ^a   Decruyenaere, J ^a   Jaqmin, P ^b   De Beule, K ^b   Van Peer, A ^b   Woestenborghs, R ^b   Groen, K ^b   Colardyn, F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; HYDROXYITRACONAZOLE; ITRACONAZOLE;

ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYCOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE;

EID: 0030732294     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.12.2714     Document Type: Article

References (17)

1. Beckhouse, M. J., I. M. Whyte, P. L. Byth, J. C. Napier, and A. J. Smith. 1988. Altered aminoglycosidc pharmacokinetics in the critically ill. Anaesth. Intensive Care 16:418-422.
2. Boogaerts, M. Unpublished data.
3. Boucher, B., D. Kuhl, and W. L. Hickerson. 1992. Pharmacokinetics of systemically administered antibiotics in patients with thermal injury. Clin. Infect. Dis. 14:458-463.
4. De Beule, K., P. Jacqmin, A. Van Peer, P. Stoffels, and J. Heykants. 1995. The pharmacokinetic rationale behind intravenous itraconazole, abstr. A75, p. 14. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. De Beule, K. 1996. Itraconazole: pharmacology, clinical experience and future development. Int. J. Antimicrob. Agents 6:175-181.
6. Dupont, B., and E. Drouhet. 1987. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results. Rev. Infect. Dis. 9(Suppl. 1):71-76.
7. Espinel-Ingroff, A., S. Shadomy, and R. J. Gebhart. 1984. In vitro studies with R 51,211 (itraconazole). Antimicrob. Agents Chemother. 26:5-9.
8. Grant, S. M., and S. P. Clissold. 1989. Itraconazole: a review of its pharmacodynamic and pharmocokinctic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37:310-344.
9. Hardin, T., J. Graybill, R. Fetchick, R. Woestenborghs, M. Rinaldi, and J. Kuhn. 1988. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob. Agents Chemother. 32:1310-1313.
10. Heykants, J., A. Van Peer, V. Van de Velde, P. Van Rooy, W. Meuldermans, K. Lavrijsen, R. Woestenborghs, J. Van Cutsem, and G. Cauwenbergh. 1989. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32:(Suppl. 1):67-87.
11. Jacqmin, P. Unpublished data.
12. Lippert, H., and H. Lehmann. 1978. SI units in medicine. Urban and Schwartzenberg, Baltimore, Md.
13. Miyazaki, H. M., S. Kohno, Y. Miyazaki, K. Mitsutake, K. Tomono, M. Kaku, H. Koga, and K. Hara. 1993. Efficacy of intravenous itraconazole against experimental pulmonary itraconazole. Antimicrob. Agents Chemother. 37:2762-2765.
14. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
15. Reed, L. R., A. H. Miller-Crotchett, P. Crotchett, and J. Fisher. 1989. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. J. Trauma 29:1462-1470.
16. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. 1997. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in-vitro and in-vivo correlation data for fluconazole, itraconazole and Candida infections. Clin. Infect. Dis. 24:235-247.
17. Zaske, D., R. Cipolle, and R. Strate. 1980. Gentamycin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery 87:164-169.